Nirvana Life Sciences Cash Flow Statement

Financials in millions CAD. Fiscal year is May - April.

Millions CAD. Fiscal year is May - Apr.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '26 Jan 31, 2026	Apr '25 Apr 30, 2025	Apr '24 Apr 30, 2024	Apr '23 Apr 30, 2023	Apr '22 Apr 30, 2022	Apr '21 Apr 30, 2021
Net Income	-0.36	-0.37	-0.87	-1.49	-5.65	-0.73
Depreciation & Amortization	-	-	0.02	0.09	0.09	0.03
Asset Writedown & Restructuring Costs	-	-	0.16	0.25	-	-
Stock-Based Compensation	0.02	0.02	0.18	0.2	-	-
Provision & Write-off of Bad Debts	-	-	-	-	0.32	-
Other Operating Activities	0.18	-0	-0.03	0.23	4.48	0.08
Change in Accounts Payable	-0.01	0.07	0.03	0.05	-0.1	0.02
Change in Other Net Operating Assets	-0.7	0.21	0.33	0.32	0.38	-0.05
Operating Cash Flow	-0.88	-0.07	-0.19	-0.33	-0.49	-0.65
Capital Expenditures	-	-	-	-	-	-0.55
Cash Acquisitions	-	-	-	-	0.11	-
Other Investing Activities	-	-	-	-	-0.21	-0.12
Investing Cash Flow	-	-	-	-	-0.1	-0.67
Short-Term Debt Issued	-	0.07	0.03	0.05	0	-
Total Debt Issued	0.06	0.07	0.03	0.05	0	-
Net Debt Issued (Repaid)	0.06	0.07	0.03	0.05	0	-
Issuance of Common Stock	0.95	-	0.15	0.26	-	2.09
Other Financing Activities	0	-	-	-	-	-0.02
Financing Cash Flow	1.01	0.07	0.18	0.31	0	2.07
Net Cash Flow	0.01	0	-0.01	-0.02	-0.59	0.75
Free Cash Flow	-0.88	-0.07	-0.19	-0.33	-0.49	-1.2
Free Cash Flow Per Share	-0.04	-0.01	-0.04	-0.10	-0.13	-0.35
Levered Free Cash Flow	-0.92	0.08	-0.03	-0.09	0.03	-
Unlevered Free Cash Flow	-0.92	0.08	-0.03	-0.08	0.03	-
Change in Working Capital	-0.71	0.28	0.36	0.38	0.28	-0.03

Source: S&P Global Market Intelligence. Standard template. Financial Sources.